

Supplemental Table for:
Phase 2 and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
S. M. Tolaney et al.

Table S1. Cabozantinib dose modification.

	<i>n</i> (%)	Weeks
Dose Held	34 (97)	69
Reason		
Toxicity	26 (74)	57
PPE	7 (20)	23
Diarrhea	3 (9)	5
Other toxicity	16 (46)	29
Other (patient error, etc.)	8 (23)	12
Dose Reduced	12 (34)	13
Reason		
Toxicity	12 (34)	13
PPE	4 (11)	5
Other toxicity ^a	8 (23)	8

^a Including elevated alanine aminotransferase (*n*=1), diarrhea (*n*=1), hypertension (*n*=1), mucositis (*n*=1), pancreatitis (*n*=1), proteinuria (*n*=1), transaminitis (*n*=1), and other (*n*=1).
PPE, palmar-plantar erythrodysesthesia.